Generic Oncology Sterile Injectable Market - Trends and Forecast till 2025 | Key Players Eli Lilly & Company, Pfizer Inc., Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd.

Generic oncology sterile injectables are used in treatment of various types of cancers such as ovarian, breast, and lung. These drugs are relatively cheaper than branded counterparts. This is owing presence of same active ingredients, although its inactive contents are different. Cost is a major concern for cancer patients, especially in emerging economies such as India, Brazil, and China. Therefore, governments of such countries are taking efforts to reduce cost of medications and increase its accessibility. For instance, the National Pharmaceutical Pricing Authority (NPPA) of India reduced the prices of a few cancer drugs by 86% in March 2017. Generic oncology sterile injectables have a huge potential in such countries, where patient population is high; however, spending power is relatively low. Furthermore, patent expiry is expected to fuel growth of the generic oncology sterile injectables during the forecast period. Also, the emergence of biosimilars has also impacted growth of generics drugs. For instance, according to the Journal of Generics and Biosimilars Initiative, 2017, biosimilars had a major share in Europe since 2013 and in the U.S. since 2015 and the share of biosimilars is expected to increase significantly in the biologicals market. This is expected to eventually boost growth of the generic oncology sterile injectable market.

Download PDF Brochure for Research @ https://www.coherentmarketinsights.com/insight/request-pdf/562

Market Dynamics

Generic oncology sterile injectables market is gaining significant traction due to rising prevalence of cancer cases. For instance, according to the National Cancer Institute, in 2016, around 1,685,210 new cases of cancers were reported in the U.S. Manufacturers are focusing on launching new products to offer low cost treatment to patients. For instance, in November, 2017, Mylan N.V. launched Clofarabine Injection (20 mg/20 mL (1 mg/mL) Single-Dose Vials) following U.S. Food and Drug administration approval in the U.S. market. Clofarabine is a generic version of Genzyme's Clolar, which is used for treatment of refractory acute lymphoblastic leukemia for patients aged 1 year to 21 years.

Expansion of manufacturing facilities and mergers between key players to develop strong pipeline product is expected to propel the generic oncology sterile injectable market growth

Manufacturers in the market are focusing on collaboration and expansion of manufacturing facilities to tap into emerging markets. For instance, In July 2017, India-based Alembic Pharmaceuticals established an oncology manufacturing facility for injectables and lyophilized products in Gujarat. The manufacturing site has a capacity for 60 million tablets and capsules, approximately 20 million vials capacity for liquid injectables and lyophilized product. This new manufacturing facility will develop oncology injectables and lyophilized products for sales in international markets of the U.S., Middle East, North Africa, South Africa, and Australia. Furthermore, in December 2016 the global leader, Baxter International acquired India-based Claris Injectables for expanding its generic injectables product portfolio such as in oncology. This acquisition is expected to strengthen Baxter’s sales in hospitals in order to gain a leading position in generic injectables market.

Key features of the study:

• This report provides in-depth analysis of the generic oncology sterile injectables market and its product type, market size (US$ Million), and Cumulative Annual Growth Rate (CAGR %) for the forecast period: 2017 – 2025, considering 2016as the base year.
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players.
• It profiles leading players in the generic oncology sterile injectables market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans.
• Key companies covered as a part of this study include Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, distribution channel, market expansion, and marketing tactics.
• The generic oncology sterile injectables market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for generic oncology sterile injectables market, research and consulting firms, new entrants and financial analysts.
• Various strategy matrices used in analyzing the generic oncology sterile injectables market would provide stakeholders vital inputs to make strategic decisions accordingly.

For More Details On this Report, Click Here @ https://www.coherentmarketinsights.com/market-insight/generic-oncology-sterile-injectables-market-562

Detailed Segmentation:

• Global Generic Oncology Sterile Injectable Market, By Product Type:
◦ Chemotherapy
▪ Alkylating agents
▪ Antimetabolites
▪ Plant Alkaloids
▪ Antitumor Antibiotics
▪ Others
◦ Monoclonal Antibodies
◦ Cytokines
◦ Peptide Hormones
• Global Generic Oncology Sterile Injectable Market, By Disease Indication:
◦ Ovarian Cancer
◦ Breast Cancer
◦ Lung Cancer
◦ Pancreatic Cancer
◦ Others
• Global Generic Oncology Sterile Injectable Market, By Distribution Channel :
◦ Hospital Pharmacies
◦ Retail Pharmacies
◦ Online Pharmacies
• Global Generic Oncology Sterile Injectable Market, By Regions :
◦ North America
◦ Latin America
◦ Europe
◦ Asia Pacific
◦ Middle East
◦ Africa

Buy This Exclusive Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/562

Contact Us:

Mr. Shah
Coherent Market Insights
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.